They are even more detailed in their recommendation for PMS2 carriers and state that PMS2 carriers appear to be at no greater risk of ovarian cancer and that individuals may reasonably elect not to have an oophorectomy (12). This evidence concerns the gene PMS2 and ovarian carcinoma.